Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Change in Acquisitions & Divestments: 2019-2024

Historic Change in Acquisitions & Divestments for Nurix Therapeutics (NRIX) over the last 6 years, with Nov 2024 value amounting to $459.5 million.

  • Nurix Therapeutics' Change in Acquisitions & Divestments rose 40.93% to $156.2 million in Q3 2025 from the same period last year, while for Aug 2025 it was $597.2 million, marking a year-over-year increase of 58.58%. This contributed to the annual value of $459.5 million for FY2024, which is 42.25% up from last year.
  • Latest data reveals that Nurix Therapeutics reported Change in Acquisitions & Divestments of $459.5 million as of FY2024, which was up 42.25% from $323.0 million recorded in FY2023.
  • Over the past 5 years, Nurix Therapeutics' Change in Acquisitions & Divestments peaked at $459.5 million during FY2024, and registered a low of $25.4 million during FY2020.
  • Its 3-year average for Change in Acquisitions & Divestments is $353.8 million, with a median of $323.0 million in 2023.
  • Data for Nurix Therapeutics' Change in Acquisitions & Divestments shows a peak YoY soared of 841.60% (in 2021) over the last 5 years.
  • Yearly analysis of 5 years shows Nurix Therapeutics' Change in Acquisitions & Divestments stood at $25.4 million in 2020, then surged by 841.60% to $238.9 million in 2021, then rose by 16.70% to $278.8 million in 2022, then rose by 15.86% to $323.0 million in 2023, then surged by 42.25% to $459.5 million in 2024.